- Home
- IMCR vs USA Comparison
IMCR vs USA Comparison
Compare IMCR & USA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- USA
- Stock Information
- Founded
- IMCR 2008
- USA 1986
- Country
- IMCR United Kingdom
- USA United States
- Employees
- IMCR N/A
- USA N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- USA Finance Companies
- Sector
- IMCR Health Care
- USA Finance
- Exchange
- IMCR Nasdaq
- USA Nasdaq
- Market Cap
- IMCR 1.6B
- USA N/A
- IPO Year
- IMCR 2021
- USA N/A
- Fundamental
- Price
- IMCR $35.00
- USA $6.88
- Analyst Decision
- IMCR Buy
- USA
- Analyst Count
- IMCR 10
- USA 0
- Target Price
- IMCR $58.13
- USA N/A
- AVG Volume (30 Days)
- IMCR 383.2K
- USA 880.5K
- Earning Date
- IMCR 08-07-2025
- USA 01-01-0001
- Dividend Yield
- IMCR N/A
- USA 9.66%
- EPS Growth
- IMCR N/A
- USA N/A
- EPS
- IMCR N/A
- USA N/A
- Revenue
- IMCR $333,581,000.00
- USA N/A
- Revenue This Year
- IMCR $26.82
- USA N/A
- Revenue Next Year
- IMCR $8.15
- USA N/A
- P/E Ratio
- IMCR N/A
- USA N/A
- Revenue Growth
- IMCR 25.75
- USA N/A
- 52 Week Low
- IMCR $23.15
- USA $5.62
- 52 Week High
- IMCR $41.54
- USA $7.09
- Technical
- Relative Strength Index (RSI)
- IMCR 59.78
- USA 60.48
- Support Level
- IMCR $32.20
- USA $6.84
- Resistance Level
- IMCR $35.75
- USA $6.94
- Average True Range (ATR)
- IMCR 1.31
- USA 0.07
- MACD
- IMCR 0.28
- USA 0.01
- Stochastic Oscillator
- IMCR 84.94
- USA 82.20
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.